Navigation Links
Large Geographic Differences in EpiPen Prescriptions in the U.S.,,From the Journal of Allergy and Clinical Immunology

MILWAUKEE, July 11, 2007 /PRNewswire/ -- A new study suggests strong variation in the occurrence of anaphylaxis between the northern and southern U.S. Anaphylaxis is a severe allergic reaction that can be fatal without treatment with epinephrine. The striking north-south differences in EpiPen prescribing, a marker of anaphylaxis risk, currently are without explanation. The investigators hypothesize, however, that low levels of vitamin D from lack of sunshine, may play a role and that this hypothesis requires further investigation.

The study, "Regional differences in EpiPen prescriptions in the United States: The potential role of vitamin D," can be found in the July 2007 issue of the Journal of Allergy and Clinical Immunology (JACI), the peer-reviewed journal of the American Academy of Allergy, Asthma and Immunology (AAAAI).

Carlos A. Camargo, MD, DrPH, FAAAAI, and colleagues obtained data on EpiPen prescriptions in 2004 for all 50 states and Washington, D.C. They used state populations to calculate the average number of prescriptions written per person.

Researchers found that on average, there were 5.71 EpiPens prescribed per 1000 persons in the U.S. The highest number of prescriptions per 1000 persons was in Massachusetts with 11.8. Hawaii had the lowest with 2.7 prescriptions per 1000 persons.

The team also found a regional difference in the number of prescriptions. New England had the highest values with 8 to 12 EpiPen prescriptions per 1000 persons, and southern states had only 3 prescriptions per 1000 persons. These findings persisted even after adjusting for differences in population characteristics, healthcare data and other factors.

The explanation for the strong variation between northern states and southern states is not clear. The investigators note, however, that southern states have a warmer climate and more year-round sunlight and that their findings support rec
'"/>




Page: 1 2

Related medicine technology :

1. Urinalysis Analyzers: Large Capabilities in Every Size Device
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
5. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
6. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
7. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
8. Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
9. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
10. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:5/21/2013)... ALLENTOWN, Pa. , May 21, 2013  Lehigh ... additional TRU-D SmartUVC TM devices, adding to its ... With seven devices taking up residence within the network, ... in the U.S. to proactively combat superbugs and provide ... Short for Total Room Ultraviolet Disinfector, TRU-D – the ...
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... VIEW, Calif., June 23 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... present,results of its Phase 2a clinical trial of ... at the 50th Annual Scientific Meeting of,the American ... Boston,Copley Place in Boston, MA. The oral platform ...
... data from,PAREXEL International Corporation (Nasdaq: PRXL ), ... new,industry-sponsored clinical trial initiations, or starts, surged another ... analysis shows that the,biopharmaceutical industry submitted 662 commercial ... clinical studies for drugs in,2007, up from the ...
Cached Medicine Technology:Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...
(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) A paper recently ... and co-written by physicians and scientists at the ... important genetic risk factor for pulmonary fibrosis can be ... lung disease. , Researchers looked at a fairly common ... is a component of the mucous produced by the ...
(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 2013 While North Carolina is synonymous ... travel guides. Brunswick Plantation & Golf Resort is synonymous ... access to 27 holes of "Top10" championship golf. ... Carolina, knowing the Top 10 from an ... the overwhelming task of selecting the course to play. ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... for diabetes and heart disease, such as high blood ... risk typical of obesity, but they represent only a ... long-term study. The results will be presented Saturday at ... "Some obese persons have a normal cardiovascular risk ...
... ... product line. , ... Germantown, WI (PRWEB) June 19, 2010 -- Ellsworth Adhesives announced today it ... Rapid Seal® line offers high-performance, flexible, chemical resistant sealants that are designed for a ...
... June 2010: Achieving disease remission in patients with ... of socio-economic importance including work productivity and quality ... EULAR 2010, the Annual Congress of the European ... Austrian findings are reported in addition to improvements ...
... ... dedication among healthcare professionals. This awards program salutes the individual health care ... the patients and family members they serve in every sector of the ... Press Club in Washington, D.C., on October 4, where the award winners ...
... for many with low risk disease, researchers find , ... prostate cancer that has a low risk of progression, ... a suitable treatment option, according to a large-scale study ... to treat localized prostate cancer is controversial because, especially ...
... ... Gynecologic Oncologist Mildred Ridgway, MD is now performing a new procedure at Baptist Medical ... Removing uterine fibroids is referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, ...
Cached Medicine News:Health News:Certain obese people are not at high risk of heart disease, diabetes 2Health News:Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering 2Health News:Targeting disease remission has socio-economic benefits over low disease activity 2Health News:Targeting disease remission has socio-economic benefits over low disease activity 3Health News:Dorland Health People Awards Accepting Entries through Friday, June 25, 2010 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2
... Eyes enzymatic cleaner is a ... removes stubborn deposits in as ... eyes enzymatic cleaner contains an ... irritating film on soft contact ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Titanium. Straight shafts with curved lower tip. Upper tip fits into positioning hole while lower jaw stabilizes the lens. Flat smooth handle with dull finish. Most popular size or model....
Medicine Products: